普伐他汀可抑制肝癌细胞增殖和 MAT1A 表达的增加，并在体内模型中发挥作用。
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models.
机构信息
Department of Gastroenterology, Donostia Hospital, Instituto Biodonostia, University of the Basque Country EHU/UPV, Ciberehd, San Sebastián, Spain.
出版信息
Cancer Cell Int. 2012 Feb 21;12:5. doi: 10.1186/1475-2867-12-5.
BACKGROUND
Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models.
METHOD
We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels.
RESULTS
We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).
CONCLUSION
The combination of pravastatin + sorafenib were more effective than Sorafenib alone.
背景
他汀类药物可能对肝癌（HCC）有治疗作用。这种疾病是肝脏最常见的恶性原发性肿瘤。我们的目的是确定普伐他汀在体外和体内模型中是否具有治疗作用。
方法
我们设计了体外和体内模型。在体外，我们使用 PLC 并确定细胞增殖。在体内，我们使用动物模型来确定 PCNA 和 MAT1A 的表达和转氨基酶水平。
结果
我们发现普伐他汀可降低体外细胞增殖（普伐他汀组细胞增殖为 82%，索拉非尼组为 51%，联合组为 40%）和体内细胞增殖（普伐他汀组为 80%，索拉非尼组为 76.4%，联合组为 72.72%）。普伐他汀组 MAT1A 水平明显升高（D 62%，P 94%，S 71%，P+S 91%）。转氨基酶水平在普伐他汀组明显降低（GOT 和 GPT 水平 D 619.5 U/L；271 U/L）（P 117.5 U/L；43.5 U/L）（S 147 U/L；59 U/L）（P+S 142 U/L；59 U/L）。
结论
普伐他汀+索拉非尼联合治疗比单独使用索拉非尼更有效。
Zotero 插件